The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
High-fidelity PAMless base editing of hematopoietic stem cells to treat chronic granulomatous disease
Abstract
X-linked chronic granulomatous disease (X-CGD) is an inborn error of immunity (IEI) resulting from genetic mutations in the cytochrome b-245 beta chain ( CYBB ) gene. The applicability of base editors (BEs) to correct mutations that cause X-CGD is constrained by the requirement of Cas enzymes to recognize specific protospacer adjacent motifs (PAMs). Our recently engineered PAMless Cas enzyme, SpRY, can overcome the PAM limitation. However, the efficiency, specificity, and applicability of SpRY-based BEs to correct mutations in human hematopoietic stem and progenitor cells (HSPCs) have not been thoroughly examined. Here, we demonstrated that the adenine BE ABE8e-SpRY can access a range of target sites in HSPCs to correct mutations causative of X-CGD. For the prototypical X-CGD mutation CYBB c.676C>T, ABE8e-SpRY achieved up to 70% correction, reaching efficiencies greater than three-and-one-half times higher than previous CRISPR nuclease and donor template approaches. We profiled potential off-target DNA edits, transcriptome-wide RNA edits, and chromosomal perturbations in base-edited HSPCs, which together revealed minimal off-target or bystander edits. Edited alleles persisted after transplantation of the base-edited HSPCs into immunodeficient mice. Together, these investigational new drug–enabling studies demonstrated efficient and precise correction of an X-CGD mutation with PAMless BEs, supporting a first-in-human clinical trial (NCT06325709) and providing a potential blueprint for treatment of other IEI mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At a median follow-up of 6 years after gene therapy, most patients with early cALD had importantly not developed major functional abnormalities.”
From Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy (2025) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeted capture and massively parallel sequencing of 12 human exomes
Ng, S. B., Turner, E. H., Robertson, P. D., Flygare, S. D., Bigham, A. W., Lee, C., Shaffer, T., Wong, M., Bhattacharjee, A., Eichler, E. E., et al. (2009) · Nature · doi:10.1038/nature08250 · Cited by 2,030
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.-S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031054 · Cited by 1,962
Engineered CRISPR-Cas9 nucleases with altered PAM specificities
Kleinstiver, B. P., Prew, M. S., Tsai, S. Q., Topkar, V. V., Nguyen, N. T., Zheng, Z., Gonzales, A. P. W., Li, Z., Peterson, R. T., Yeh, J.-R. J., et al. (2015) · Nature · doi:10.1038/nature14592 · Cited by 1,624
Self-citationTargeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems
Nishida, K., Arazoe, T., Yachie, N., Banno, S., Kakimoto, M., Tabata, M., Mochizuki, M., Miyabe, A., Araki, M., Hara, K. Y., et al. (2016) · Science · doi:10.1126/science.aaf8729 · Cited by 1,349
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants
Walton, R. T., Christie, K. A., Whittaker, M. N., & Kleinstiver, B. P. (2020) · Science · doi:10.1126/science.aba8853 · Cited by 1,233
Self-citationRichter, M. F., Zhao, K. T., Eton, E., Lapinaite, A., Newby, G. A., Thuronyi, B. W., Wilson, C., Koblan, L. W., Zeng, J., Bauer, D. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0453-z · Cited by 1,020
Vakulskas, C. A., Dever, D. P., Rettig, G. R., Turk, R., Jacobi, A. M., Collingwood, M. A., Bode, N. M., McNeill, M. S., Yan, S., Camarena, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0137-0 · Cited by 782 · cited 3×
“( I ) a- to-G editing efficiency of the target c.676c > T adenine in heterozygous heK 293T CYBB c.676c > T cells, using fidelity-enhanced aBes ( 40 , 41 ).”
Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors
Grünewald, J., Zhou, R., Garcia, S. P., Iyer, S., Lareau, C. A., Aryee, M. J., & Joung, J. K. (2019) · Nature · doi:10.1038/s41586-019-1161-z · Cited by 663
Residual NADPH Oxidase and Survival in Chronic Granulomatous Disease
Kuhns, D. B., Alvord, W. G., Heller, T., Feld, J. J., Pike, K. M., Marciano, B. E., Uzel, G., DeRavin, S. S., Priel, D. A. L., Soule, B. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007097 · Cited by 568
Self-citation
Research works printed but not linked: 69
- 10.1126/scitranslmed.aad8856 · DOI · Paper page
- 10.1038/s41591-019-0735-5 · DOI · Paper page
- 10.1016/j.jaci.2019.03.012 · DOI
- 10.1016/S2352-3026(19)30021-3 · DOI
- 10.1038/s41467-022-31344-x · DOI · Paper page
- 10.1038/3233 · DOI
- 10.1038/sj.cgt.7700232 · DOI
- 10.1038/s41591-020-0790-y · DOI
- 10.1038/s41588-023-01434-7 · DOI
- 10.1056/NEJMoa2300709 · DOI
- 10.1097/00005792-200005000-00003 · DOI · Paper page
- 10.1093/cid/ciu1154 · DOI
- 10.1542/peds.114.2.462 · DOI
- 10.1038/s41588-021-00838-7 · DOI · Paper page
- 10.1038/s41556-019-0425-z · DOI
- 10.1038/nbt.4317 · DOI
- 10.1038/s41588-020-0623-4 · DOI · Paper page
- 10.1038/nbt.4192 · DOI · Paper page
- 10.1038/ncomms15178 · DOI
- 10.1038/nature24644 · DOI · Paper page
- 10.1038/nbt.3803 · DOI · Paper page
- 10.1038/nature17946 · DOI · Paper page
- 10.1038/s41596-021-00525-1 · DOI
- 10.1038/s41573-020-0084-6 · DOI
- 10.1126/science.1225829 · DOI · Paper page
- 10.1038/nbt.2508 · DOI · Paper page
- 10.1038/s41477-020-00827-4 · DOI
- 10.1111/pbi.13838 · DOI · Paper page
- 10.1038/s41467-022-30228-4 · DOI
- 10.1038/s41467-022-31034-8 · DOI
- 10.1038/nature16526 · DOI · Paper page
- 10.1038/s41587-019-0254-4 · DOI
- 10.1016/j.tig.2021.09.002 · DOI
- 10.1038/s41587-020-0412-8 · DOI
- 10.1007/978-1-0716-2879-9_5 · DOI
- 10.1182/blood.2021011192 · DOI
- 10.1182/blood.2020008503 · DOI
- 10.3389/fgeed.2022.923718 · DOI
- 10.1016/j.bbmt.2020.09.031 · DOI
- 10.1038/nbt.3290 · DOI · Paper page
- 10.1016/j.stem.2010.06.014 · DOI · Paper page
- 10.1182/blood.V77.6.1218.1218 · DOI
- 10.1084/jem.172.1.363 · DOI
- 10.1038/bcj.2011.35 · DOI
- 10.1038/s41587-020-0555-7 · DOI
- 10.14797/mdcj-10-1-3 · DOI
- 10.1038/s41587-024-02142-1 · DOI
- 10.1126/scitranslmed.aan0820 · DOI · Paper page
- 10.1038/nbt.4172 · DOI · Paper page
- 10.1517/14712598.8.6.725 · DOI
- 10.1007/s00294-021-01211-1 · DOI
- 10.1126/sciadv.aax5717 · DOI
- 10.3389/fimmu.2022.1067417 · DOI
- 10.1038/s41587-020-0491-6 · DOI
- 10.1038/s41587-023-01915-4 · DOI · Paper page
- 10.1038/s41586-019-1711-4 · DOI · Paper page
- 10.1038/s41576-022-00541-1 · DOI
- 10.1038/s41587-023-01947-w · DOI
- 10.1038/s41587-024-02324-x · DOI
- 10.1038/s41587-019-0032-3 · DOI
- 10.1038/s41587-020-0562-8 · DOI
- 10.1038/s41587-022-01492-y · DOI
- 10.1101/gr.275579.121 · DOI
- 10.1038/s41592-018-0051-x · DOI
- 10.1186/s13059-016-1029-6 · DOI
- 10.1101/861054 · DOI
- 10.1038/s41525-021-00227-3 · DOI
- 10.1016/0888-7543(92)90147-K · DOI
- 10.1002/gcc.2870040311 · DOI
Cited by
Ex vivo modification of hematopoietic stem and progenitor cells for gene therapy
Williams, D. A., Kohn, D. B., & Thrasher, A. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.058 · Cited by 11
Metadata
- Authors
- Bzhilyanskaya, V., Ma, L., Liu, S., Fox, L. R., Whittaker, M. N., Meis, R. J., Choi, U., Lawson, A., Ma, M., Theobald, N., Burkett, S., Sweeney, C. L., Lazzarotto, C. R., Tsai, S. Q., Lack, J. B., Wu, X., Dahl, G. A., Malech, H. L., Kleinstiver, B. P., & De Ravin, S. S.
- Affiliations
- Genetic Immunotherapy Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
- Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
- Molecular Cytogenetic Core Facility, Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.
- CELLSCRIPT, Madison, WI 53713, USA.
- Department of Hematology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA.
- Bioinformatics (NCBR)/Integrated Data Sciences Section (IDSS), Research Technology Branch/DIR/NIAID, Frederick, MD 21702, USA.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2024-10-16
- Volume
- 16
- Issue
- 769
- ISSN
- 1946-6234
- 1946-6242
- PMC
- PMC11753194
- Cited by
- 28
- References
- 14
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review